Sara Jane Ward

Dr. Sara Jane Ward

Temple University Lewis Katz School of Medicine
+1

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2014 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SWSara Jane Ward
Sara Jane Ward
SMSean D McAllister
Sean D McAllister
RKRumi Kawamura
Rumi Kawamura
RMRyuchi Murase
Ryuchi Murase
HNHarshini Neelakantan
Harshini Neelakantan
EWEllen A Walker
Ellen A Walker
Background and Purpose: Paclitaxel (PAC) is associated with chemotherapy‐induced neuropathic pain (CIPN) that can lead to the cessation of treatment in cancer patients even in the absence of alternate therapies. We previously reported that chronic administration of the non‐psychoactive cannabinoid cannabidiol (CBD) prevents PAC‐induced mechanical and thermal sensitivity in mice. Hence, we sought to determine receptor mechanisms by which CBD inhibits CIPN and whether CBD negatively effects nervous system function or chemotherapy efficacy.Experimental Approach: The ability of acute CBD pretreatment to prevent PAC‐induced mechanical sensitivity was assessed, as was the effect of CBD on place conditioning and on an operant‐conditioned learning and memory task. The potential interaction of CBD and PAC on breast cancer cell viability was determined using the MTT assay.Key Results: PAC‐induced mechanical sensitivity was prevented by administration of CBD (2.5 – 10 mg·kg−1) in female C57Bl/6 mice. This effect was reversed by co‐administration of the 5‐HT1A antagonist WAY 100635, but not the CB1 antagonist SR141716 or the CB2 antagonist SR144528. CBD produced no conditioned rewarding effects and did not affect conditioned learning and memory. Also, CBD + PAC combinations produce additive to synergistic inhibition of breast cancer cell viability.Conclusions and Implications: Our data suggest that CBD is protective against PAC‐induced neurotoxicity mediated in part by the 5‐HT1A receptor system. Furthermore, CBD treatment was devoid of conditioned rewarding effects or cognitive impairment and did not attenuate PAC‐induced inhibition of breast cancer cell viability. Hence, adjunct treatment with CBD during PAC chemotherapy may be safe and effective in the prevention or attenuation of CIPN.

27 July 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
KKKirsten M King
Kirsten M King
AMAlyssa M Myers
Alyssa M Myers
ASAriele J Soroka‐Monzo
Ariele J Soroka‐Monzo
RTRonald F Tuma
Ronald F Tuma
RTRonald J Tallarida
Ronald J Tallarida
SWSara Jane Ward
Sara Jane Ward

1 October 2011 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
SWSara Jane Ward
Sara Jane Ward
MRMichael David Ramirez
Michael David Ramirez
HNHarshini Neelakantan
Harshini Neelakantan
EWEllen Ann Walker
Ellen Ann Walker
Odynia in male and female C57Bl/6 mice. Because the nonpsychoactive phytocannabinoid cannabidiol attenuates other forms of neuropathic pain, we assessed its effect on paclitaxel-induced allodynia. Paclitaxel produced allodynia that was largely dose independent and more robust in female mice, and this effect was prevented by treatment with cannabidiol. Our preliminary findings therefore indicate that cannabidiol may prevent the development of paclitaxel-induced allodynia in mice and therefore be effective at preventing dose-limiting paclitaxel-induced peripheral neuropathy in humans....

1 December 2009 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
SWSara Jane Ward
Sara Jane Ward
MRMarisa Rosenberg
Marisa Rosenberg
LDLinda A. Dykstra
Linda A. Dykstra
EWEllen A. Walker
Ellen A. Walker